Evidence map›Paper›PMID 33727634›Full record

Trial reportScientific reports2021

S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils.

Adéla Navrátilová, Viktor Bečvář, Jiří Baloun, Dres Damgaard, Claus Henrik Nielsen, David Veigl, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt, Lucie Andrés Cerezo

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. [Advances in the pathogenesis and treatment of neutrophils in chronic sinusitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Adéla NavrátilováInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Viktor BečvářInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Jiří BalounInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Dres DamgaardInstitute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Claus Henrik NielsenInstitute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
David VeiglFirst Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Karel PavelkaInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Jiří VencovskýInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Ladislav ŠenoltInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic.
Lucie Andrés CerezoInstitute of Rheumatology, Na Slupi 4, 12850, Prague, Czech Republic. andres-cerezo@revma.cz.
Charles University · CZInstitute of Rheumatology · CZCopenhagen University Hospital · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

S100A11 (calgizzarin), a member of S100 family, is associated with several autoimmune diseases, including rheumatoid arthritis (RA). Neutrophil extracellular traps (NETs) are implicated in the pathogenesis of RA and in the externalization of some S100 family members. Therefore, we aimed to determine the association between S100A11 and NETs in RA. For this purpose, the levels of S100A11 and NETosis markers were detected in the RA synovial fluid by immunoassays. The expression of S100A11 by neutrophils in the RA synovial tissue was assessed. Neutrophils isolated from peripheral blood were exposed to S100A11 or stimulated to release NETs. The levels of NETosis- and inflammation-associated proteins were analysed by immunoassays. NETs were visualized by immunofluorescence. We showed that S100A11 was expressed by the neutrophils in the RA synovial tissue. Moreover, S100A11 in the RA synovial fluid correlated with several NETosis markers. In vitro, S100A11 was abundantly released by neutrophils undergoing NETosis compared to untreated cells (p < 0.001). Extracellular S100A11 increased the secretion of IL-6 (p < 0.05) and TNF (p < 0.05) by neutrophils but did not induce NETosis. This study demonstrates, for the first time, that the release of S100A11 is dependent on NETosis and that extracellular S100A11 augments the inflammatory response by inducing pro-inflammatory cytokines in neutrophils.

Indexed as

AdultAgedArthritis, RheumatoidExtracellular TrapsFemaleHumansInterleukin-6MaleMiddle AgedNeutrophilsS100 ProteinsSynovial FluidTumor Necrosis Factor-alphaIL6 protein, humanInterleukin-6S100A11 protein, humanS100 ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID33727634
PMCPMC7966750
OpenAlexW3137668411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.